Comparison of Nebivolol and Bisoprolol for Cardiovascular Mortality in Hypertensive Patients.

Ratan Kumar,Jamila Begum,Kheraj Mal,Faizan Shaukat

doi:10.7759/cureus.6453

Abstract

IntroductionBeta-blockers again are now considered as first-line therapy for various cardiovascular diseases. In this study, we compare the cardiovascular event between two beta-blocker, i.e. Nebivolol and Bisoprolol.Materials and MethodsIt is a two-arm open-label randomized prospective study that was conducted from 1st Jan 2016 to 30th July 2019 in tertiary care hospital, Nawabshah. One thousand and fifty-six (n=1056) hypertensive patients were enrolled after informed consent, which were randomized into two equal groups. Patients were followed up for one year.ResultsComparison between Nebivolol and Bisoprolol showed that all-cause mortality (9.8% vs 11.48%), cardiovascular mortality (5.4% vs 7.0%), all-cause hospitalization (14.4% vs 16.3%), and cardiovascular hospitalization (9.8% vs 12.09%) was numerically lower in nebivolol but the difference was not statistically significant.ConclusionFurther large scale multicentric trials with a longer follow up period are needed to compare various beta-blockers for cardiovascular event.

Highlights

Beta-blockers again are considered as first-line therapy for various cardiovascular diseases
Comparison between Nebivolol and Bisoprolol showed that all-cause mortality (9.8% vs 11.48%), cardiovascular mortality (5.4% vs 7.0%), all-cause hospitalization (14.4% vs 16.3%), and cardiovascular hospitalization (9.8% vs 12.09%) was numerically lower in nebivolol but the difference was not statistically significant
Continuous variables including age, blood pressure (BP), and duration of hypertension were analyzed via descriptive statistics and were presented as mean and standard deviation (SD) while categorical variables, including gender, smoking history, and cardiovascular outcomes were presented by percentages and frequencies

Summary

Materials and Methods

It is a two-arm open-label randomized prospective study that was conducted from 1 st Jan 2016 to 30th July 2019 in tertiary care hospital, Nawabshah. One thousand and fifty-six (n=1056) hypertensive patients were enrolled after informed consent, which were randomized into two equal groups. Patients were followed up for one year

Results

Conclusion

Materials And Methods

Discussion

Conclusions

Disclosures